A pilot study to evaluate a community pharmacy-based monitoring system to identify adverse drug reactions associated with paediatric medicines use

European Journal of Clinical Pharmacology

Volumn 66, Issue 6, 2010, Pages 627-632

  Tobaiqy, Mansour ^c   Stewart, Derek ^a   Helms, Peter J ^c   Bond, Christine ^c   Lee, Amanda Jane ^c   Bateman, Nick ^b   McCaig, Dorothy ^a   McLay, James ^c  

^a ROBERT GORDON UNIVERSITY   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Adverse drug reactions; Children; Pharmacovigilance; Questionnaire

Indexed keywords

ANTICONVULSIVE AGENT; ATOMOXETINE; CARBAMAZEPINE; DEXAMPHETAMINE; DIAZEPAM; ETIRACETAM; FLUOXETINE; LAMOTRIGINE; MELATONIN; METHYLPHENIDATE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; VALPROIC ACID; PROPYLAMINE;

APPETITE DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; AUDITORY HALLUCINATION; CLINICAL EVALUATION; DECREASED APPETITE; DISEASE DURATION; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SURVEILLANCE PROGRAM; FATIGUE; FEEDING DISORDER; HUMAN; INCREASED APPETITE; MENTAL DISEASE; MOOD DISORDER; NAUSEA; PATIENT SAFETY; PEDIATRICS; PHARMACIST; PHARMACY; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; SIDE EFFECT; SLEEP DISORDER; STOMACH DISEASE; TREATMENT RESPONSE; WEIGHT CHANGE; WEIGHT GAIN; ADOLESCENT; CHEMICALLY INDUCED DISORDER; CHILD; DRUG TOXICITY; HOSPITALIZATION; INCIDENCE; INFANT; NEWBORN; ORGANIZATION AND MANAGEMENT; PRESCHOOL CHILD; PROSPECTIVE STUDY; SAMPLE SIZE; STATISTICS; UNITED KINGDOM;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DRUG TOXICITY; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MELATONIN; METHYLPHENIDATE; PHARMACIES; PILOT PROJECTS; PROPYLAMINES; PROSPECTIVE STUDIES; QUESTIONNAIRES; SAMPLE SIZE; SCOTLAND; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 77954912782     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0790-9     Document Type: Article

References (18)

1. Choonara I (2004) Direct reporting of suspected adverse drug reactions by patients. J R Soc Med 97:316-317
2. Rawlins MD (1995) Pharmacovigilance: paradise lost, regained or postponed? J R Coll Physicians Lond 29(1):41-49
3. Belton KJ, Lewis SC, Payne S, Rawlins MD, Wood SM (1995) Attitudinal survey of ADR reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol 39:223-226
4. Carleton BC, Smith MA, Gelin MN, Heathcote SC (2006) Paediatric adverse drug reaction reporting: understanding and future directions. Can J Clin Pharmacol 14(1):45-57
5. McLay JS, Tanaka M, Ekins-Daukes S, Helms PJ (2006) A prospective questionnaire assessment of attitudes and experiences of off label prescribing amongst hospital based paediatricians. Arch Dis Child 91:584-587
6. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M (2001) Incidence of adverse drug reactions in paediatric in/out patients: a systematic review and meta-analysis of prospective studies. BJCP 52(1):77-83
7. Turner S, Nunn AJ, Fielding K, Choonara I (1999) Adverse drug reactions to unlicensed and off-label drugs on paediatric wards. Acta Paediatr 88(9):965-968
8. Jonville-Bera AP, Giraudeau B, Blanc P, Beau-Salinas F, Autret-Leca E (2002) Frequency of adverse drug reactions in children: a prospective study. BJCP 53(2):207-210
9. Weiss J, Krebs S, Hoffman C, Werner U, Neubert A, Brune K, Rascher W (2002) Survey of adverse drug reactions on a paediatric ward: a strategy for early and detailed detection. Pediatrics 110(2 Pt 1):254-257
10. Kramer MS, Hutchinson TA, Flegel KM, Naimark L, Contardi R, Leduc DG (1985) Adverse drug reactions in general paediatric outpatients. J Pediatrics 106(2):305-310
11. Adis International (2005) Pilot schemes for patient reporting of suspected ADRs have been launched in the UK. Reactions 1 (1035):2-2(1)
12. Committee on Safety of Medicines (2005) Selective serotonin reuptake inhibitors: overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents including a summary of available safety and efficacy data. http://www.mhra.gov.uk/Safetyinformation/ Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON019494. Accessed Nov 2008
13. Bennet K, Tealing M, Feely J (2005) Overprescribing of antidepressants to children: pharmacoepidemiological study in primary care. BMJ 331(7530):1451
14. Clarkson I, Choonara I (2002) Surveillance for fatal suspected adverse drug reactions in the UK. Arc Dis Child 87:462-467 (Pubitemid 35440692)
15. Scottish Medicines Consortium (2005) Atomoxetine. NHS Scotland 2005-10-25.
16. Stewart D, Helms PJ, Bond CM, McCaig D, McLay JS (2005) Monitoring adverse drug reactions in children using community pharmacies: a pilot study. Br J Clin Pharmacol 59:677-683
17. Armour C, Brillant M, Krass I (2007) Pharmacists' views on involvement in pharmacy practice research: strategies for facilitating participation. Pharmacy Practice 5(2):59-66
18. Faber A, De Jong-van, den Berg L, Netjes K, Kalverdijk L, Minderaa R, Tobi H (2005) Recruitment of parents and physicians of stimulant-using children via community pharmacies is successful. J Clin Epidemiol 58:1072-1073